SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN)GlobeNewsWire • 10/24/19
European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue SarcomaGlobeNewsWire • 09/24/19
SpringWorks Therapeutics Announces Closing Of Initial Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional SharesGlobeNewsWire • 09/17/19